{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:59:16Z","timestamp":1761101956718},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":684,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jval.2011.02.1177","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T22:25:30Z","timestamp":1311459930000},"page":"961-963","source":"Crossref","is-referenced-by-count":10,"title":["Funding Linked to Ongoing Research: Impact of the Bosentan Patient Registry on Pricing in Australia"],"prefix":"10.1016","volume":"14","author":[{"given":"John","family":"Wlodarczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Pater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2006","series-title":"Selected measures for managing subsidised drug use in the pharmaceutical benefits scheme","key":"10.1016\/j.jval.2011.02.1177_bib1"},{"year":"2006","series-title":"Endoluminal grafting for abdominal aortic aneurysm","key":"10.1016\/j.jval.2011.02.1177_bib2"},{"year":"2007","series-title":"MSAC brochure","key":"10.1016\/j.jval.2011.02.1177_bib3"},{"key":"10.1016\/j.jval.2011.02.1177_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.18553\/jmcp.2009.15.8.683","article-title":"Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals","volume":"15","author":"Carlson","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jval.2011.02.1177_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2011.02.1177_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/11531050-000000000-00000","article-title":"Access with evidence development: the US experience","volume":"28","author":"Mohr","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2011.02.1177_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","article-title":"Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products","volume":"28","author":"Towse","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2011.02.1177_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with evidence development: applications and issues","volume":"26","author":"Trueman","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2011.02.1177_bib9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00019053-200624090-00007","article-title":"Public funding of bosentan for the treatment of pulmonary artery hypertension (PAH) in Australia: cost-effectiveness and risk sharing","volume":"24","author":"Wlodarczyk","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2011.02.1177_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2011.02.1177_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2011.02.1177_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3111\/13696990802034525","article-title":"A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian pharmaceutical benefits scheme: the bosentan patient registry","volume":"11","author":"Owen","year":"2008","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2011.02.1177_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1445-5994.2009.02139.x","article-title":"The bosentan patient registry: long-term survival in pulmonary arterial hypertension","volume":"41","author":"Keogh","year":"2011","journal-title":"Intern Med J"},{"issue":"Suppl 3","key":"10.1016\/j.jval.2011.02.1177_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2362.2006.01688.x","article-title":"Survival in patients with pulmonary arterial hypertension treated with first-line bosentan","volume":"36","author":"McLaughlin","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jval.2011.02.1177_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1378\/chest.123.2.344","article-title":"Haemodynamics and survival in pateints with pulmonary arterial hypertension related to systemic sclerosis","volume":"123","author":"Kawut","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jval.2011.02.1177_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients","volume":"35","author":"Koh","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jval.2011.02.1177_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00019053-200826070-00002","article-title":"Pharmaceutical risk-sharing agreements","volume":"26","author":"Cook","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2011.02.1177_bib18","series-title":"The New York Times","article-title":"Pricing pills by the result","author":"Pollack","year":"2007"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511013179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511013179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T16:23:14Z","timestamp":1638116594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301511013179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1098301511013179"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2011.02.1177","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}